1.Evaluation of bone marrow involvement in leukemic patients using bone marrow scan.
Jae Hyun CHO ; Myoung Joon KIM ; Jong Doo LEE ; Chang Yoon PARK ; Kill Young KIM ; Yong Soo KIM
Korean Journal of Nuclear Medicine 1993;27(2):298-304
No abstract available.
Bone Marrow*
;
Humans
2.Transcriptional REpression of Vimentin Gene During All-TTrans Retinoic Acid-Induced Differentiation of HL-60 Cells.
Kyu LIM ; Do Won KWON ; Seung Min KIM ; Kyung Ah YOON ; Mi Young SON ; Myoung Sun LEE ; Jong Il PARK ; Wan Hee YOON ; Byung Doo HWANG
Journal of Korean Society of Endocrinology 1998;13(4):601-611
BACKGROUND: Vimentin is the major intermediate-size filament in the cytoplasm of cells from mesenchymal origin. The HL-60 cell is a unique human leukemic cell line capable of terminal differentiation with several chemical inducers, and then the cell line becomes a fre#quently described model system for cell differentiation in vitro. Vimentin mRNA is reduced during all-trans retinoic acid (retinoic acid) -dependent differentication but increased by 12-0-tetradecanoylphorbol-13-acetate (TPA). In this paper, we have investigated on the mechanism of transcriptional repression of vimentin gene during retinoic acid-dependent differentication of HL-60 cell. METHODS: HL-60 cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotics in a humidified 5% CO at 37C. Total RNA was prepared by a modification of the method of Karlinsey et al. Northern blot hybridization was performed by the method of Virca et al. EcoRI fragment of pVIM-GEM was used as probe for vimentin mRNA. DNA mobility shift assay was performed by the method of Lim et al. End labeled DNA probe (Upper strand, 5-CGCITGATGAGTCAGCCG-3) for AP-1 binding activity was mixed with nuclear extracts in a 20 pL reaction volume containing 300 mM KCI, 60 mM HEPES, pH 7.9, 25mM MgC1, 1mM EDTA, 1mM DTT, 60% glycerol, and 2 pg of poly[dI-dC]. RESULTS: The level of vimentin mRNA was decreased at 12 hours after retinoic acid treatment, and not detected at 48 hours. The level of vimentin mRNA was reduced in proportion to concentration of retinoic acid, Retinoic acid-reduced vimentin mRNA was no change in cells treated with cycloheximide. Retinoic acid-dependent decrease of vimentin mRNA was partially recovered by staurosporin pretreatment. In DNA mobility shift assay, AP-1 binding activity was reduced at 48 hr during retinoic acid-induced differentiation. CONCLUSION: These results suggest that the transcriptional repression of vimentin gene during retinoic acid-induced differentiation in HL-60 cells is correlated with reduction of DNA binding activity of AP-1.
Anti-Bacterial Agents
;
Blotting, Northern
;
Cell Differentiation
;
Cell Line
;
Cycloheximide
;
Cytoplasm
;
DNA
;
Edetic Acid
;
Electrophoretic Mobility Shift Assay
;
Glycerol
;
HEPES
;
HL-60 Cells*
;
Humans
;
Hydrogen-Ion Concentration
;
Repression, Psychology*
;
RNA
;
RNA, Messenger
;
Transcription Factor AP-1
;
Tretinoin
;
Vimentin*
3.The Effect of Low Dose and High Dose ACTH in the Evaluation of Adrenal Function.
Hyung Joon YOO ; Sung Hee IHM ; Sung Woo PARK ; Jae Hwan JEE ; Hyun Kyu KIM ; Doo Man KIM ; Jae Myoung YOO ; Moon Ki CHOI
Journal of Korean Society of Endocrinology 1998;13(4):580-589
BACKGROUND: Pharmacological ACTH test provide information only about the ability of the adrenal gland to respond to unusual stimuli and may not reflect the daily cortisol secretion. There were some controversies in the diagnosis of mild adrenal insufficiency by using a pharmacological dose of ACTH. The purpose of the present study was to assess and compare the effect of low dose 1 pg ACTH and high dose 249 pg ACTH in the evaluation of adrenal function. The intravenous injection of a pharmacological dose(250 pg) of ACTH has been used as a standard test in the initial assessment of adrenal function. So we low dose ACTH to evaluate the adrenal function and compare the result of high dose ACTH. METHOD: Basal serum cortisol sampling was done at 2:00 p.m.. And after 1 pg ACTH iv bolus injection, cortisol sampling was done at 20, 30, 45 and 60 min respectively. On the next day same procedure was repeated at same time, but 249 mg ACTH was given instead of the low dose. Normal adrenal function was diagnosed with the criteria of stimulated serum cortisol concentration over 20 mg/dL. Total 65 patients took part in this study. Three hypopituitarism patients and one Addisons disease were included. Sixty-one patients had the history of glucocorticoid ingestion or had physical findings of cushingoid features with symptoms suggest the adrenal insufficiency. RESULTS: Sixteen patients showed normal response to both low dose and high dose ACTH. Thirty-six patients were not stimulated to both low dose and high dose ACTH. The remaining thirteen patients revealed normal response to high dose ACTH, but not to low dose ACTH. CONCLUSION: It appears that low dose ACTH stimulation test is more sensitive and specific than high dose ACTH and is capable of revealing mild adrenal insufficiency.
Addison Disease
;
Adrenal Glands
;
Adrenal Insufficiency
;
Adrenocorticotropic Hormone*
;
Diagnosis
;
Eating
;
Humans
;
Hydrocortisone
;
Hypopituitarism
;
Injections, Intravenous
4.A Case with Isolated ACTH Deficiency
Myoung Sik KIM ; Byung Doo LEE ; Sang Min SHIN ; Young Il KIM ; Byung Oh JEONG ; Hong Jib CHOI ; Phil Ho KIM ; Kyung Soo KO ; Jae Hong PARK
Journal of Korean Society of Endocrinology 1996;11(4):538-543
Isolated ACTH deficiency is a rare cause of secondary adrenocortical insufficiency. Adrenal crisis in isolated ACTH deficiency is less common compared to primary adrenal insufficiency, but isolated ACTH deficiency is an important cause of hypoglycemia. Recently we experienced a 41-year-old man admitted because of mental confusion. On admission, plasma glucose and sodium concentration were 1.7, 132 mmol/L, respectively. Basal plasma ACTH and cortisol levels were low and other pituitary hormone showed normal response to combined pituitary stimulation test except growth hormone. Plasma ACTH concentration remained low even after intravenous injection of ovine corticotropin releasing factor. It suggest that the defect of ACTH secretion was apparently due to intrinsic pituitary rather than hypothalamic disease. The sellar CT showed the fossa to be filled by cerebrospinal fluid. After treatment with glucocorticoid, he had no further evidence of hypoglycemia and hyponatremia. In conclusion, we report a case of isolated ACTH deficiency with empty sella.
Addison Disease
;
Adrenocorticotropic Hormone
;
Adult
;
Blood Glucose
;
Cerebrospinal Fluid
;
Corticotropin-Releasing Hormone
;
Growth Hormone
;
Humans
;
Hydrocortisone
;
Hypoglycemia
;
Hyponatremia
;
Hypothalamic Diseases
;
Injections, Intravenous
;
Plasma
;
Sodium
5.An Evaluation of HLA-matched Platelet Transfusion Effect in Patients with Platelet Refractoriness.
Hyung Doo PARK ; Yang Hyun KIM ; Yoon June PARK ; Kyou Sup HAN ; Myoung Hee PARK
The Korean Journal of Laboratory Medicine 2004;24(6):426-431
BACKGROUND: Patients with platelet refractoriness as a result of human leukocyte antigen (HLA) alloimmunization can be effectively managed by transfusion of HLA-matched platelets. In this study, we have retrospectively evaluated the effect of HLA-matched platelet transfusion using a hospital based donor pool of 450 HLA typed donors. METHODS: For 17 patients showing platelet refractoriness to random donor platelets [1 hr corrected count increment (CCI) <7, 500/microliter/m2; mean 1, 887/microliter/m2] and HLA alloimmunization, 78 single-donor apheresis platelets from 62 donors were transfused. HLA compatible donors were selected based on HLA match and patients' HLA antibody specificities. RESULTS: An average of 4.6 transfusions per patient were done and effective post-transfusion platelet increments were obtained with a mean 1 hr CCI of 17, 813/microliter/m2. In 76% (59/78) of the total transfusions, an effective platelet increment (1 hr CCI > or =7, 500/microliter/m2) was obtained. HLA crossmatch (NIH method) negative patients showed a significantly higher platelet increment compared with crossmatch positive patients (23, 877 vs 10, 823; P=0.000). Although better transfusion effect was obtained in higher grade HLA match of A-B2U by selection of HLA compatible donors according to patients' HLA antibody specificities, an effective platelet increment was obtained in lower grade matches as well. Platelets transfused < or =24 hours after collection showed a significantly higher platelet increment compared with those stored >24 hours (20, 325 vs 11, 417; P=0.029). CONCLUSIONS: Although many low grade matched donors were selected due to a relatively small size of HLA typed donor pool, effective platelet increments were obtained by selecting platelet donors on the basis of HLA antibody specificity.
Antibody Specificity
;
Blood Component Removal
;
Blood Platelets*
;
Humans
;
Leukocytes
;
Platelet Transfusion*
;
Retrospective Studies
;
Tissue Donors
6.A Case of Cushing's Syndrome in Pregnancy due to Adrenal Adenoma.
Hyung Joon YOO ; Sung Hee IHM ; Sung Woo PARK ; Hae Sung YIM ; Yong Tae KIM ; Chul Hee PARK ; Hyun Kyu KIM ; Doo Man KIM ; Jae Myoung YOO ; Moon Ki CHOI
Journal of Korean Society of Endocrinology 1998;13(2):264-270
Cushings syndrome in pregnancy is rare. This is explained by the syndromes association with amencerhea, infertility and abortions. Matemal and fetal risks increase markedly when pregnancy does occur in woman with hypercortisolism. Since pregnant women without Cushings syndrome develop some features of Cushings syndrome, such as hypertension, hyperglycemia and striae, a high index of clinical suspician must be maintained to prevent delay in diagnosis. The physiologic changes in adrenocorticostemid metabolism during pregnancy further complieate the diagnosis. We describe a case of Cushings syndmme in pregnancy secondary to an adrenal cortical adenoma which was diagnosed immediately after a preterm delivery in 24-year-old woman with preeclampsia.
Adenoma*
;
Adrenocortical Adenoma
;
Cushing Syndrome*
;
Diagnosis
;
Female
;
Humans
;
Hyperglycemia
;
Hypertension
;
Infertility
;
Metabolism
;
Pre-Eclampsia
;
Pregnancy*
;
Pregnant Women
;
Young Adult
7.Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06).
Jae Myoung NOH ; Won PARK ; Jae Sung KIM ; Woong Sub KOOM ; Jin Hee KIM ; Doo Ho CHOI ; Hee Chul PARK
Cancer Research and Treatment 2014;46(3):243-249
PURPOSE: The aim of this study was to examine the clinical implications of a pathologically complete response after neoadjuvant chemoradiotherapy (CRT) followed by local excision for patients with cT2 rectal cancer who refused radical surgery. MATERIALS AND METHODS: Seventeen patients with cT2 primary rectal cancer within 6 cm from the anal verge who received neoadjuvant CRT and local excision because of patient refusal of radical surgery or poor performance status were included. Two patients had clinical involvement of a regional lymph node. Preoperative radiotherapy was delivered to the whole pelvis at a dose of 44 to 50.4 Gy in 22 to 28 fractions. All patients underwent transanal excision and eight patients (47%) received postoperative chemotherapy. RESULTS: Ten patients (59%) achieved ypT0. At a median follow-up period of 75 months (range, 22 to 126 months), four (24%) patients developed recurrence (two locoregional and two distant). The 5-year disease-free survival of all patients was 82%, and was higher in patients with ypT0 (90%) than in patients with ypT1-2 (69%, p=0.1643). Decreased disease-free survival was also observed in patients receiving capecitabine compared with 5-fluorouracil (54% vs. 100%, p=0.0298). CONCLUSION: Local excision could be a feasible alternative to radical surgery in patients with ypT0 after neoadjuvant CRT for cT2 distal rectal cancer without further radical surgery.
Chemoradiotherapy*
;
Disease-Free Survival
;
Disulfiram
;
Drug Therapy
;
Fluorouracil
;
Follow-Up Studies
;
Humans
;
Lymph Nodes
;
Neoadjuvant Therapy
;
Pelvis
;
Radiotherapy
;
Rectal Neoplasms*
;
Recurrence
;
Retrospective Studies*
;
Capecitabine
8.A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer.
Jae Myoung NOH ; Won PARK ; Seung Jae HUH ; Doo Ho CHOI ; Jung Hyun YANG ; Seok Jin NAM ; Jeong Han KIM ; Young Hyuck IM ; Jin Seok AHN
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2008;26(1):10-16
PURPOSE: To compare the treatment outcomes and to analyze prognostic factors between the use of a breast-conserving treatment (BCT) and a mastectomy for early stage breast cancer. MATERIALS AND METHODS: We retrospectively reviewed 1,200 patients with pathological stage T1-2N0 breast cancer who received surgery between September 1994 and December 2002 at Samsung Medical Center. We compared the patient characteristics and treatment outcomes between the two treatment groups. RESULTS: Among the 1,174 eligible patients, 601 (51.2%) patients received a BCT and the remaining 573 (48.8%) patients received a mastectomy. The mastectomy group of patients had significantly more cases with a larger tumor size, multicentricity, extensive intraductal component, and estrogen- and progesterone-receptor negativity. The ten-year overall survival rates (OS) of the BCT and mastectomy groups were 91.96% and 91.01%, respectively (p=0.1274). The ten-year disease-free survival rates (DFS) were 80.48% for the BCT group of patients and 84.95% for the mastectomy group of patients, respectively (p=0.8795). CONCLUSION: Our study shows some differences in patient characteristics between the two treatment groups. However, these differences did not result in significant survival differences.
Breast Neoplasms
9.Patterns of Recurrence after Breast-Conserving Treatment for Early Stage Breast Cancer by Molecular Subtype.
Jae Myoung NOH ; Doo Ho CHOI ; Seung Jae HUH ; Won PARK ; Jung Hyun YANG ; Seok Jin NAM ; Young Hyuck IM ; Jin Seok AHN
Journal of Breast Cancer 2011;14(1):46-51
PURPOSE: To study clinical features and patterns of recurrence after breast-conserving treatment (BCT) for three molecular subtypes of early stage breast cancer. METHODS: The sample studied included 596 patients with T1-2N0-1 breast cancer who received BCT. Three groups were defined by receptor status. Luminal: estrogen receptor (ER) or progesterone receptor (PR) positive; triple negative (TN): ER, PR, and epidermal growth factor receptor-2 (HER2) receptor negative; and HER2 overexpressing: ER and PR negative but HER2 receptor positive. RESULTS: The number of patients in each group was 408 (68.5%), 105 (17.6%), and 83 (13.9%), respectively. The median follow-up period was 79 months. The TN and HER2 subtypes occurred in younger patients (p=0.0007) and had higher nuclear grade and poorer histologic grade (p<0.0001 and 0.0071, respectively). During the follow-up period, locoregional recurrence was detected as the first site of recurrence in 26 (6.4%), 11 (10.5%), and 9 (10.8%) patients in the luminal, TN, and HER2 subtypes, respectively (p=0.1924). Thirty-one (7.6%), 7 (6.7%), and 7 (8.4%) patients in each group had distant metastases as the first sign of recurrence (p=0.8996). Median time to locoregional and distant recurrence was shorter in the HER2 subtype (p=0.0889 and 0.0780, respectively), and the HER2 subtype was significantly associated with poor overall survival (p=0.0009). CONCLUSION: After BCT in Korean women with early stage breast cancer, the patterns of recurrence were not different among the molecular subtypes, although the TN and HER2 subtypes were associated with younger age, higher nuclear grade, and poorer histologic grade.
Breast
;
Breast Neoplasms
;
Epidermal Growth Factor
;
Estrogens
;
Female
;
Follow-Up Studies
;
Humans
;
Mastectomy, Segmental
;
Neoplasm Metastasis
;
Phenobarbital
;
Receptor, erbB-2
;
Receptors, Estrogen
;
Receptors, Progesterone
;
Recurrence
10.Evaluation of Hemoglobin A1c on the Cobas Integra 800 Immunoassay and Tosoh HLC-723 G8 HPLC Analyzer.
Hyung Doo PARK ; Hee Jung KIM ; Myoung Soo KIM ; Soo Youn LEE ; Jong Won KIM
Journal of Laboratory Medicine and Quality Assurance 2009;31(2):239-246
BACKGROUND: Hemoglobin A1c (HbA1c) is a good marker for the monitoring of glycemic control in patients with diabetes mellitus and various methods are used for determination of HbA1c. We evaluated the analytical performance of ion-exchange high-performance liquid chromatography system, standard mode (G8 SM) and variant mode (G8 VM) of Tosoh HLC-723 G8 (Tosoh Corporation, Japan) and Cobas Integra 800 (Roche Diagnostics, Germany) using new reagent (Tina-quant Hemoglobin A1c Gen.2, Roche Diagnostics) for immunoassay. METHODS: G8 SM, G8 VM, and Cobas Integra 800 were evaluated for linearity, precision, comparison of method, and speed. Variant II Turbo (Bio-Rad Laboratories, USA) was used for comparison test for above three analyzers. RESULTS: Three instruments showed within-run precision (CVs) of 0.52-1.12% in low level and 0.39-0.90% in high level control material. Total run precision (CVs) were in 0.95-1.26% in low level and 0.60-0.94% in high level control material. The linearity was good for the range of 4-15% and comparison with Variant II turbo was excellent with 0.9878-0.9977 of correlation coefficient. Analytical speed was 2 min/1 min in G8 SM, 3.5 min/1.5 min in G8 VM, and 14.7 min/18 sec in Cobas Integra 800, respectively. CONCLUSIONS: HLC-723 G8 SM and VM, and Cobas Integra 800 were showed excellent linearity, precision, and comparison with other instrument. We should consider the characteristics including analytical method and speed in each instrument when clinical laboratory is planning to introduce different equipment for HbA1c determination.
Chromatography, High Pressure Liquid
;
Chromatography, Liquid
;
Diabetes Mellitus
;
Hemoglobins
;
Humans
;
Immunoassay